查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011526

疫苗契約製造市場：2026-2032年全球市場預測（依疫苗類型、技術平台、服務內容、應用、研發階段及最終用戶分類）

Vaccine Contract Manufacturing Market by Vaccine Type, Technology Platform, Service Offering, Application Type, Application Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，疫苗契約製造市場價值將達到 60.4 億美元，到 2026 年將成長至 65.6 億美元，到 2032 年將達到 114.3 億美元，複合年成長率為 9.53%。

主要市場統計數據
基準年 2025 60.4億美元
預計年份：2026年 65.6億美元
預測年份 2032 114.3億美元
複合年成長率 (%) 9.53%

從策略觀點來看，契約製造是塑造公共衛生結果、加快商業化速度和增強跨境韌性的關鍵能力。

疫苗契約製造環境已從單一的供應解決方案發展成為支持全球公共衛生、市場化藥物研發和地緣政治韌性的策略支柱。製造商、研發人員和政策制定者日益將契約製造視為一種靈活可配置的能力，它會影響專案進度安排、監管風險和病患獲取途徑。因此，決策者需要一個整合的觀點，將技術能力與涵蓋製劑、填充和包裝、分析表徵以及物流等各個環節的服務協調聯繫起來。

技術創新、監管靈活性和綜合服務模式如何重新定義契約製造的競爭優勢。

過去五年，企業採購生產和研究服務的方式發生了顯著變化。 mRNA和病毒載體平台的進步、模組化和一次性設施架構的普及，以及基於細胞和無細胞技術的興起，拓寬了可行的專案設計範圍。這些技術變革也帶來了營運方面的進步。更先進的分析技術縮短了研發週期，灌裝和包裝流程的自動化降低了變異性，並加快了規模化生產進程。

評估近期美國關稅趨勢如何重塑疫苗製造領域的籌資策略、供應商合格和區域投資決策。

美國新的貿易政策和關稅方案帶來了新的成本和營運方面的考量，正在影響全球供應鏈。關稅相關的摩擦增加了進口原料、一次性零件和專用設備的總到岸成本，促使贊助商和製造商重新評估其籌資策略策略。為此，各組織正在實現供應商多元化，認證關鍵投入品的區域替代品，並加快庫存規劃，以確保專案持續運作。

基於細分的詳細洞察，將疫苗模式、平台架構、服務產品、部署階段和最終用戶行為與夥伴關係和投資選擇連結起來。

精準的細分觀點能夠清楚揭示策略價值的集中之處以及能力缺口所在。在分析DNA疫苗、去活化疫苗、減毒疫苗、mRNA疫苗、類毒素疫苗和病毒載體疫苗等多種疫苗類型時，企業必須將技術要求與生產製造專長相匹配，因為每種疫苗類型都有其獨特的上游和下游製程要求以及監管環境。技術平台進一步細分了這些要求。以細胞為基礎的方法分為貼壁培養和懸浮培養，而無細胞、卵源性和合成胜肽平台則各自面臨著規模化生產和分析方面的挑戰。

區域生產能力、監管多樣性和供應鏈走廊決定了疫苗生產投資在哪些方面能夠帶來策略韌性和商業性優勢。

區域趨勢決定了在哪些地區投資產能和技術能力能帶來最大的策略回報。在美洲，人們傾向於快速獲得先進的生物製劑平台，並與夥伴關係建立良好的關係，透過聯合部署技術團隊和強大的分析能力來縮短研發週期。該地區的監管路徑強調與國際標準接軌，並通常支持優先項目的快速核准，這反過來又促進了本地生產以及先進填充和包裝能力的開發。

策略行動、產能投資和夥伴關係模式，重點是扶持疫苗生產領域表現優異的契約製造製造商和服務供應商。

疫苗契約製造領域的企業競爭格局受垂直整合、平台專業化和服務範圍策略投資的影響。主要企業透過整合分析服務和研發專長來脫穎而出，從而減少技術轉移摩擦，縮短臨床試驗時間。而其他企業則專注於模組化生產能力和靈活的一次性生產，以適應多種治療方法，而無需進行大規模設備改造。從產能共用協議到技術授權和合資模式，夥伴關係和策略夥伴關係已成為彌合產能缺口和加速向新地區擴張的常用機制。

為加速疫苗計畫的成功，提出協調技術能力、供應鏈韌性、合約模式和社區參與的實用建議。

為了將洞察轉化為競爭優勢，產業領導者應專注於有針對性、可操作的步驟，以降低專案風險並加速商業化進程。首先，應優先考慮能力匹配，將疫苗研發模式和階段與合作夥伴的專長領域相匹配。這將縮短技術轉移時間，並最大限度地減少規模化生產過程中的返工。其次，應透過認證多家關鍵原料和一次性組件供應商，並制定包含區域採購和庫存緩衝的緊急時應對計畫，來增強供應鏈的穩健性。

透明的混合方法研究設計，結合對關鍵相關人員的訪談、監管和技術證據以及交叉檢驗的綜合分析，為策略決策提供支援。

本研究採用混合方法，旨在檢驗來自多個資料來源和相關人員觀點的證據，從而支持上述發現。主要數據透過契約製造、疫苗研發公司、監管顧問和採購機構高管進行結構化訪談收集，以了解實際營運和策略重點。二級資訊來源包括同儕審查文獻、監管指導文件、專利趨勢和企業技術揭露，用於檢驗有關技術趨勢和能力的論點。

整合策略挑戰，展現綜合能力設計、供應鏈韌性和夥伴關係協調如何決定專案和公共衛生結果。

技術創新、監管現代化和地緣政治壓力等多種因素共同作用，重新定義了契約製造的優先事項。成功的機構將平台特定的卓越技術與一體化的服務交付、穩健的供應鏈策略以及基於當地實際情況的投資決策相結合。本分析強調了將從mRNA和病毒載體到蛋白質平台等不同疫苗生產方式的要求與相應的生產架構和分析能力相匹配的重要性，同時也要考慮生物技術公司、政府機構和製藥公司採購行為的實際情況。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：疫苗契約製造：依疫苗類型分類

  • DNA
  • 失活
  • 活病毒疫苗
  • mRNA
  • 類毒素
  • 病毒載體

第9章：按技術平台分類的疫苗契約製造市場

  • 基於細胞
    • 黏附培養
    • 懸浮培養
  • 無細胞
  • 蛋製品
  • 合成胜肽

第10章：疫苗契約製造市場（依服務類型分類）

  • 分析服務
  • 原料藥生產
  • 填充和精加工
  • 藥學服務
  • 後勤
  • 包裝

第11章：按應用分類的疫苗契約製造市場

  • 預防性疫苗
  • 治療性疫苗

第12章：按應用階段分類的疫苗契約製造市場

  • 臨床階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 商業階段

第13章：疫苗契約製造市場：依最終用戶分類

  • 生技公司
  • 政府機構
  • 製藥公司

第14章：疫苗契約製造市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：疫苗契約製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：疫苗契約製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國疫苗契約製造市場

第18章：中國疫苗契約製造市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Ajinomoto Co., Inc.
  • Aton（Shanghai）Biotech Co., Ltd.
  • Avid Bioservices, Inc.
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • CSL Limited
  • Curia Global, Inc.
  • Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • Emergent BioSolutions Inc.
  • FUJIFILM Diosynth Biotechnologies USA, Inc. by FUJIFILM Corporation
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • ICON PLC
  • IDT Biologika GmbH
  • KBI Biopharma, Inc. by JSR Corporation
  • Klocke Pharma-Service GmbH
  • Lonza Group Ltd.
  • Merck KGaA
  • Moderna, Inc.
  • Pfizer Inc.
  • Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • Recipharm AB
  • Serum Institute of India
  • Vetter Pharma-Fertigung GmbH & Co. KG
Product Code: MRR-430D42AA0DC4

The Vaccine Contract Manufacturing Market was valued at USD 6.04 billion in 2025 and is projected to grow to USD 6.56 billion in 2026, with a CAGR of 9.53%, reaching USD 11.43 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.04 billion
Estimated Year [2026] USD 6.56 billion
Forecast Year [2032] USD 11.43 billion
CAGR (%) 9.53%

A strategic orientation that frames vaccine contract manufacturing as a critical capability shaping public health outcomes, commercialization speed, and cross-border resilience

The vaccine contract manufacturing landscape has evolved from a narrowly focused supply solution into a strategic axis of global public health, commercial drug development, and geopolitical resilience. Manufacturers, developers, and policy leaders are increasingly treating contract manufacturing as a configurable capability that shapes program timelines, regulatory risk, and patient access. As a result, decision-makers need an integrated perspective that connects technological competency with service orchestration across formulation, fill-finish, analytical characterization, and logistics.

This introduction sets the stage for that integrated perspective by highlighting how technological advances, regulatory expectations, and geopolitical pressures together create both risk and opportunity. It outlines the critical vectors that influence partner selection and capability investment: vaccine modality diversity, platform complexity, service scope, clinical and commercial stage requirements, and end-user priorities. By linking operational capabilities to strategic outcomes, the narrative that follows helps executive teams prioritize near-term actions-such as securing dual-source supply chains or accelerating validation of single-use systems-while keeping sight of longer-term imperatives like regional manufacturing capacity and workforce continuity. Transitioning from awareness to structured decision-making requires clarity about the interplay between science, regulation, and logistics; the content that follows offers that clarity in actionable terms.

How technological innovation, regulatory agility, and integrated service models are redefining competitive advantage in contract vaccine manufacturing

The past five years have produced transformative shifts that are changing how organizations source manufacturing and scientific services. Advances in mRNA and viral vector platforms, greater acceptance of modular and single-use facility architectures, and the emergence of cell-based and cell-free technologies have expanded the palette of feasible program designs. These technical shifts are accompanied by operational advances: more sophisticated analytics shorten development cycles, and automation in fill-finish reduces variability and accelerates scale-up timelines.

Concurrently, regulatory authorities have signaled a willingness to adopt more adaptive review pathways and rely on real-world data to support post-authorization monitoring. This regulatory evolution encourages sponsors and manufacturers to co-develop validation strategies that are field-ready and data-driven. Market participants are responding by forming deeper, capability-driven partnerships rather than one-off transactional contracts. As a result, contract manufacturers are moving upstream into drug substance work, formulation development, and integrated analytics to become full lifecycle partners. Taken together, these shifts create a new playing field where technological agility, regulatory savvy, and service integration determine competitive advantage and program resilience.

Assessment of how recent United States tariff dynamics are reshaping procurement strategies, supplier qualification, and regional investment decisions across vaccine manufacturing

Emerging trade policies and tariff scenarios in the United States introduced new cost and operational considerations that reverberate across global supply chains. Tariff-related frictions increase the total landed cost of imported raw materials, single-use components, and specialized instrumentation, prompting sponsors and manufacturers to reassess sourcing strategies. In response, organizations are diversifying supplier bases, qualifying regional substitutes for critical inputs, and accelerating inventory planning to protect program continuity.

The tariffs also influence location decisions for capital investments. Investors and strategic teams now weigh the resilience benefits of near-shore or on-shore capacity against the fixed cost advantages of established offshore capabilities. This calculus has prompted greater interest in establishing regional hubs that reduce exposure to cross-border trade policy volatility while preserving access to skilled labor pools and regulatory familiarity. In parallel, contract manufacturers are enhancing supply chain transparency and investing in procurement capabilities to mitigate tariff impacts. These operational responses reduce the likelihood of sudden program interruptions and enable sponsors to maintain timelines by adopting multi-modal logistics and local sourcing strategies where feasible.

Deep segmentation-driven insights that map vaccine modalities, platform architectures, service offerings, application stages, and end-user behaviors to partnership and investment choices

A nuanced segmentation lens clarifies where strategic value is concentrated and where capability gaps persist. When analyzing vaccine type diversity-spanning DNA, inactivated, live attenuated, mRNA, toxoid, and viral vector modalities-organizations must align technical requirements with manufacturing specialization, because each modality carries distinct upstream and downstream process needs and regulatory touchpoints. Technology platforms further stratify requirements: cell-based approaches are divided between adherent cell culture and suspension cell culture, while cell-free, egg-based, and synthetic peptide platforms introduce their own scale-up and analytical challenges.

Service offering segmentation reveals varying levels of integration and margin potential, with analytical services, drug substance manufacturing, fill-finish, formulation services, logistics, and packaging each demanding specific capabilities and quality systems. Application type differentiation into preventive and therapeutic vaccines influences batch release strategies, potency assays, and post-market surveillance approaches. Application stage is also material to partner selection: clinical-stage programs-spanning Phase I, Phase II, and Phase III studies-require flexible manufacturing and rapid change control, whereas commercial-stage programs demand validated capacity, sustained supply agreements, and mature quality management systems. Finally, end-user categories-biotech companies, government agencies, and pharmaceutical companies-bring differing procurement behaviors, risk tolerances, and contracting preferences, which in turn shape the structure of commercial contracts and technical transfer expectations.

Regional capacity, regulatory diversity, and supply chain corridors that determine where vaccine manufacturing investments yield strategic resilience and commercial advantage

Regional dynamics determine where investments in capacity and capability will deliver the greatest strategic returns. The Americas prioritize rapid access to advanced biologics platforms and tend to favor partnerships that compress development timelines through co-located technical teams and robust analytics. Regulatory pathways in the region emphasize alignment with international standards and often support accelerated access for priority programs, which in turn incentivizes local manufacturing and advanced fill-finish capabilities.

Europe, Middle East & Africa present a diverse regulatory and commercial tapestry that rewards flexible, regionally distributed manufacturing footprints. In these regions, harmonization efforts and cross-border procurement programs make strategic collaboration attractive, particularly when governments and agencies seek to build resilience. Asia-Pacific is characterized by a mix of high-capacity industrial infrastructure and emerging localized innovation hubs; market participants there emphasize scalable platforms, cost-efficient production, and increasingly sophisticated contract development and manufacturing organizations. Transitioning from regional analysis to action requires an appreciation for how local regulatory expectations, workforce availability, and logistics corridors intersect with technology selection and long-term supply agreements.

Strategic behaviors, capability investments, and partnership models that distinguish high-performing contract manufacturers and service providers in vaccine production

Competitive dynamics among companies operating in the contract vaccine manufacturing space are shaped by strategic investments in vertical integration, platform specialization, and service breadth. Leading organizations are differentiating by embedding analytical services and development expertise to reduce technical transfer friction and shorten time-to-clinic. Others emphasize modular capacity and flexible single-use manufacturing to serve a broader set of modalities without extensive retooling. Alliances and strategic partnerships-ranging from capacity-sharing agreements to technology licensing and joint venture models-are common mechanisms for closing capability gaps and accelerating access to new geographies.

At the capability level, firms that demonstrate consistent quality performance in fill-finish, robust cold chain logistics, and validated formulation approaches secure preferential contracting with large sponsors and public purchasers. Investment in digital quality systems and data integrity frameworks has become a non-negotiable differentiator, enabling remote audits and streamlined regulatory interactions. From a commercial posture, organizations offering tailored contracting terms-such as flexible capacity reservation, milestone-based payments, and shared-risk models-tend to win programs where speed and predictability are equally valued. The competitive landscape thus rewards not only technical excellence but also commercial creativity and operational transparency.

Actionable recommendations for aligning technical capability, supply chain resilience, contracting models, and regional engagement to accelerate vaccine program success

To translate insight into competitive advantage, industry leaders should focus on targeted, actionable steps that reduce program risk and accelerate commercial progress. First, prioritize capability alignment by matching vaccine modality and development stage with partner specialization; this reduces technical transfer time and minimizes rework during scale-up. Next, strengthen supply chain robustness by qualifying multiple suppliers for critical raw materials and single-use components, and by developing contingency plans that include regional sourcing and inventory buffers.

Operationally, invest in modular facility designs and automation in fill-finish to increase throughput without proportionate increases in footprint or headcount. From a commercial perspective, structure contracts that balance flexibility and predictability-combining capacity reservations with performance-based milestones. Leaders should also invest in analytics and digital quality systems to enable remote oversight, faster batch release, and smoother regulatory submissions. Finally, pursue selective partnerships with local stakeholders in priority regions to reduce tariff exposure and accelerate market entry. Implementing these recommendations will require cross-functional coordination between R&D, supply chain, quality, and commercial teams, but doing so yields measurable improvements in program resilience and time-to-market.

Transparent mixed-methods research design combining primary stakeholder interviews, regulatory and technical evidence, and cross-validated synthesis to inform strategic decisions

The research underpinning these insights uses a mixed-methods approach designed to triangulate evidence from multiple data sources and stakeholder perspectives. Primary data were collected through structured interviews with senior leaders across contract manufacturing organizations, vaccine developers, regulatory advisors, and procurement authorities to capture operational realities and strategic priorities. Secondary sources included peer-reviewed literature, regulatory guidance documents, patent landscapes, and company technical disclosures to validate technological trends and capability claims.

Analytical rigor was achieved through cross-validation of qualitative inputs with process-level evidence, such as standard operating procedures, regulatory filing templates, and technology transfer case studies. Data quality safeguards included interview coding, methodological transparency, and the exclusion of claims that could not be corroborated with at least two independent sources. The approach emphasizes reproducibility and traceability so that conclusions about segmentation, regional dynamics, and tariff impacts can be followed from raw inputs through synthesis to executive recommendations. This methodology provides decision-makers with a defensible basis for procurement, capacity planning, and partnership selection.

Synthesis of strategic imperatives demonstrating how integrated capability design, supply chain resilience, and partnership alignment determine program and public health outcomes

The converging forces of technological innovation, regulatory modernization, and geopolitical pressure have redefined the priorities for vaccine contract manufacturing. Organizations that succeed will be those that combine platform-specific technical excellence with integrated service offerings, robust supply chain strategies, and regionally informed investment choices. The analysis highlights the importance of aligning modality requirements-from mRNA and viral vectors to protein-based platforms-with the appropriate manufacturing architectures and analytics capabilities, while also accounting for the realities of procurement behavior across biotech firms, government bodies, and pharmaceutical companies.

In sum, the path to resilient and efficient vaccine manufacturing lies in a balanced strategy that mitigates tariff and supply chain volatility, leverages flexible and automated production capacity, and cultivates transparent commercial partnerships. Executives should view contract manufacturing as a strategic capability to be designed, not merely purchased. By taking a deliberate, integrated approach to partner selection and capability investment, organizations can reduce program risk, compress development timelines, and improve the predictability of product supply to patients and public health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Contract Manufacturing Market, by Vaccine Type

  • 8.1. DNA
  • 8.2. Inactivated
  • 8.3. Live Attenuated
  • 8.4. MRNA
  • 8.5. Toxoid
  • 8.6. Viral Vector

9. Vaccine Contract Manufacturing Market, by Technology Platform

  • 9.1. Cell Based
    • 9.1.1. Adherent Cell Culture
    • 9.1.2. Suspension Cell Culture
  • 9.2. Cell Free
  • 9.3. Egg Based
  • 9.4. Synthetic Peptide

10. Vaccine Contract Manufacturing Market, by Service Offering

  • 10.1. Analytical Services
  • 10.2. Drug Substance Manufacturing
  • 10.3. Fill Finish
  • 10.4. Formulation Services
  • 10.5. Logistics
  • 10.6. Packaging

11. Vaccine Contract Manufacturing Market, by Application Type

  • 11.1. Preventive Vaccines
  • 11.2. Therapeutic Vaccines

12. Vaccine Contract Manufacturing Market, by Application Stage

  • 12.1. Clinical Stage
    • 12.1.1. Phase I
    • 12.1.2. Phase Ii
    • 12.1.3. Phase Iii
  • 12.2. Commercial Stage

13. Vaccine Contract Manufacturing Market, by End User

  • 13.1. Biotech Companies
  • 13.2. Government Agencies
  • 13.3. Pharmaceutical Companies

14. Vaccine Contract Manufacturing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Vaccine Contract Manufacturing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Vaccine Contract Manufacturing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Vaccine Contract Manufacturing Market

18. China Vaccine Contract Manufacturing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc
  • 19.6. Ajinomoto Co., Inc.
  • 19.7. Aton (Shanghai) Biotech Co., Ltd.
  • 19.8. Avid Bioservices, Inc.
  • 19.9. Catalent, Inc.
  • 19.10. Charles River Laboratories International, Inc.
  • 19.11. CSL Limited
  • 19.12. Curia Global, Inc.
  • 19.13. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
  • 19.14. Emergent BioSolutions Inc.
  • 19.15. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
  • 19.16. Gedeon Richter PLC
  • 19.17. GlaxoSmithKline PLC
  • 19.18. ICON PLC
  • 19.19. IDT Biologika GmbH
  • 19.20. KBI Biopharma, Inc. by JSR Corporation
  • 19.21. Klocke Pharma-Service GmbH
  • 19.22. Lonza Group Ltd.
  • 19.23. Merck KGaA
  • 19.24. Moderna, Inc.
  • 19.25. Pfizer Inc.
  • 19.26. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
  • 19.27. Recipharm AB
  • 19.28. Serum Institute of India
  • 19.29. Vetter Pharma-Fertigung GmbH & Co. KG

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ADHERENT CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUSPENSION CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY EGG BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SYNTHETIC PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FILL FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY LOGISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PREVENTIVE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COMMERCIAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GOVERNMENT AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 180. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 181. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 182. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 207. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 208. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 209. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 211. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 216. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 217. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 218. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 220. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)